Allarity Therapeutics, Inc. (ALLR)
Nasdaq · Healthcare · Biotechnology
$1.00−3.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $15.9M
- 52-week range
- $0.769 – $1.84
- 52-week change
- −40.57%
- EPS (trailing)
- −$0.79
Fiscal year to Dec 2025
- Revenue
- $320K
- Net income
- −$11.2M
- Operating margin
- −3939.1%
- Free cash flow
- −$14.8M
From the company’s annual report on SEC EDGAR.
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Headquarters: Tarpon Springs, United States · 7 employees · allarity.com